On March 17, 2022 KYORIN Holdings, Inc. reported that KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Shigeru Ogihara, "Kyorin"), a wholly owned subsidiary of KYORIN Holdings, Inc signed a license agreement with Nanjing Neiwa Faith Co., Ltd. (Head office: Nanjing, China, President & CEO: Xu Liang, "Nanjing Neiwa Faith") to grant Nanjing Neiwa Faith an exclusive license to develop and commercialize Lascufloxacin, an oral novel quinolone antibacterial drug in China (Press release, Kyorin, MAR 17, 2022, View Source [SID1234610300]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Lascufloxacin is a novel quinolone antibacterial drug manufactured by Kyorin as a new therapeutic agent for respiratory and ENT infections. In Japan, Kyorin launched the product under the name of "Lasvic Tablets 75 mg" in January 2020.
Kyorin is developing activities to provide solutions in infection-related fields in Japan. By continuously providing the latest information in the respiratory and otolaryngology fields, which are the priority areas of Kyorin, Kyorin will contribute to further treatment of infectious diseases, promote this drug in China through the alliance with Nanjing Neiwa Faith, and continue to develop global licensing activities actively.
The impact of this transaction on business performance for the fiscal year ending March 2022 is to be negligible.